Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
NRIX.OQ - Nurix Therapeutics Inc
Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference
May 20, 2026 / 05:30PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Well, let's get started. Good afternoon, everyone. Welcome back from lunch. I'm Brian Abrams, Senior Biotech Analyst here at RBC Capital Markets.
We're really pleased to have our next featured company, Nurx Therapeutics, represented by their CEO, Arthur Sands, and their CBO, Jason Kantorx.
Great. Thanks for being here. Thanks, Brian. Thanks for being here.
So maybe let's start. A little bit bigger picture on your lead program, Beckstag.
Tell us what your latest view is on the potential advantages that BTK degraders can have in the CLL space relative to the currently available inhibitors. What's out there today? And what's been your view as to the strongest
